Asset profile
pegunigalsidase alfa
Protein / enzyme therapeutic
Evidence outlook
Approved: Fabry Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
3 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 3 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pegunigalsidase Alfa: this drug | Approved | Protein / enzyme therapeutic | — | ||
| Agalsidase Beta (Fabrazyme) | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | ||
| Migalastat (Galafold) | Approved | Small molecule | Alpha-galactosidase A (GLA / α-Gal A) | ||
| Isaralgagene Civaparvovec | Not yet studied | Gene therapy / editing | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.